Navigation Links
EpiCept Corporation to Present New NP-1 Data at American Pain,Society Meeting

itionally, the study met the following secondary endpoints: a responder analysis of improvement in pain intensity (p<0.025), a responder analysis of improvement in pain relief (p<0.01), improvement in patient sleep scores (p=0.028) and overall patient global satisfaction (p=0.04). This study also found that significant neuropathic pain relief was achieved at a small fraction of the plasma levels observed after systemic dosing. The cream was found to be safe and well tolerated across all age groups studied.

"These findings add to a growing body of clinical data which demonstrate the potential for NP-1 to provide effective, additive, long-term relief to the 15 million Americans who suffer from the pain of peripheral neuropathies. The outcome from the pharmacokinetic trial in particular supports the safety of NP-1 topical cream and even more importantly its ability to be added to orally administered therapies," remarked Jack Talley, President and CEO of EpiCept. "We believe NP-1 has the largest market potential of any of our pain product candidates and we are focused on advancing it through its current Phase IIb trials. These trials are progressing as expected and we remain on track to be able to share preliminary results from the first trial by the fourth quarter of 2007.

"Current systemically-delivered analgesics have well documented limitations and significant potential side effects. The local mechanism of action of NP-1 demonstrated in these studies could reduce these side effects by blocking pain directly at its source," remarked Stephane Allard, MD, Chief Medical Officer.

EpiCept NP-1 is currently undergoing two Phase IIb trials, enrolling a total of 700 patients. The first trial is a 200 patient, placebo-controlled study of NP-1 in patients with diabetic peripheral neuropathy (DPN). More patients suffer from DPN than any other type of neuropathic pain. Only two medications are currently approved for this use. The trial is intended to confirm
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Mode of Action of EpiCept-Licensed Cancer Compound Profiled at AACR
2. Alfacell Corporation to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
3. Millipore Corporation Announces New ReNcell Data from Collaboration with ReNeuron
4. NanoBio Corporation Announces Positive Phase 1 Clinical Results for Topical Treatment for Onychomycosis
5. Alba Therapeutics Corporation Reports Preliminary Phase IIa Clinical Trial Results for AT-1001 for the Treatment of Celiac Disease
6. The Past, Present and Future of HLA Typing
7. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
8. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
10. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
11. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
Post Your Comments:
(Date:5/22/2015)... OAKS, Calif. , May 22, 2015 ... announced the Company has commenced termination of ... of brodalumab with AstraZeneca (LON:AZN, STO:AZN and ... IL-17 inhibitor, is in development for patients ... axial spondyloarthritis.  The decision was based on ...
(Date:5/22/2015)... May 22, 2015 The Assistance Fund announces ... program provides financial assistance for copay to individuals diagnosed ... announce the addition of the Melanoma Copay Assistance Program ... McGreevy , executive director. "With each additional program we ... a world where no one is denied access to ...
(Date:5/22/2015)... May 22, 2015  The U.S. Food and ... -- the first biosimilar product approved in ... toward growth in the contract manufacturing organization (CMO) ... industry is geared to the production of small-molecular ... biopharmaceutical products. The healthcare market research publisher,s report, ...
Breaking Medicine Technology:Amgen to terminate participation in co-development and commercialization of brodalumab 2Amgen to terminate participation in co-development and commercialization of brodalumab 3Amgen to terminate participation in co-development and commercialization of brodalumab 4Amgen to terminate participation in co-development and commercialization of brodalumab 5The Assistance Fund Adds Melanoma Assistance Program 2Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 2Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 3Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 4
... 2011 AMPAC Fine Chemicals LLC (AFC), a wholly ... APFC ), announced it has completed substantial plant capital ...  These capital improvements are part of several capital improvements ... FY 2011.  This semi-works facility became fully operational in ...
... CHENGDU, China, Feb. 8, 2011 /PRNewswire-Asia-FirstCall/ -- Tianyin ... ), a pharmaceutical company that develops, manufactures and ... generics and other pharmaceuticals, today announced that the ... discuss its fiscal year 2011 second quarter financial ...
Cached Medicine Technology:AMPAC Fine Chemicals Adds New Capabilities for Clinical Programs 2Tianyin Pharmaceutical Co., Inc. to Host Fiscal Year 2011 Second Quarter Earnings Conference Call on Tuesday, February 15, 2011 at 8:30 a.m. E.T. 2
(Date:5/25/2015)... York, New York (PRWEB) May 25, 2015 ... http://www.consumerinjurylawyers.com/depuy-pinnacle/lawsuit ) continue to move forward in the ... Court, Northern District of Texas. According to a ... asked the Court to modify the Case Management ... Health Information. Among other things, the Motion seeks ...
(Date:5/25/2015)... Tunstall Americas announces major investment in new technology and ... its Medical Answering Service customers. Through a combination ... now provides a seamless transition between a health care ... superior patient satisfaction. , Tunstall is pleased ... in expanded facilities and the latest telecommunication software and ...
(Date:5/24/2015)... The Rolling Stones Zip Code ... Diego at Petco Park. This iconic group is ready ... 20th, they had a warmup show in Los Angeles at ... Los Angeles, this beloved band not only played their Sticky ... such as "Jumping Jack Flash," "Moonlight Mile" and "All ...
(Date:5/24/2015)... (PRWEB) May 24, 2015 Scientists with ... paper on air quality compliance issues that may have ... workers. Surviving Mesothelioma has just posted an article on ... , The group found airborne asbestos levels well ... collected between 1984 and 2011. , “Asbestos compliance sampling ...
(Date:5/24/2015)... May 24, 2015 Indiana Fiber Network, ... announces Midwest Telecom of America, Inc. (MTA) has selected ... to Cory Childs, IFN Enterprise Sales Manager, fiber route ... “IFN’s fiber transport provides MTA with the diverse ... their Tier 1 Internet and voice carriers located at ...
Breaking Medicine News(10 mins):Health News:Federal DePuy Pinnacle Hip Lawsuits Move Forward, as Plaintiffs Seek to Modify Order Pertaining to Health Authorizations 2Health News:Federal DePuy Pinnacle Hip Lawsuits Move Forward, as Plaintiffs Seek to Modify Order Pertaining to Health Authorizations 3Health News:Tunstall Introduces New Medical Answering Service for the 21st Century Practice 2Health News:The Rolling Stones Tickets in San Diego, Orlando, Minneapolis, Dallas, Pittsburgh, Indianapolis, Atlanta, Detroit, Milwaukee, Kansas City, Columbus, Nashville & Raleigh 2Health News:New Analysis Finds Too Many Employers Ignored OSHA Asbestos Guidelines, According to Surviving Mesothelioma 2Health News:Indiana Fiber Network, LLC Enables Midwest Telecom of America with Fiber Route Diversity 2
... Netrics, a leading innovator,and provider of ... partnership with SigmaSoft International, a global supplier ... The two companies,collaborated on a new auto ... SigmaSoft recognized the need for automating the ...
... Of Support For Habitat For Humanity Continued By Binson,s Home ... Centers And Northwood Inc., Family Presented With New Home Saturday, September 22nd On Detroit,s ... ... A family will be able to,enjoy a fresh start with a new home thanks ...
... While some uncertainty does exist in climate projections and ... are likely by the 2050s, according to a recent ... and soon to be published in the November 2007 ... In metropolitan New York, researchers estimate a 47 percent ...
... MADISON, N.J., Sept. 27 Wyeth (NYSE: WYE ... position of,President and Chief Executive Officer, Wyeth, effective January ... 1986. In 1996, he was appointed,President of Wyeth- Ayerst ... pharmaceutical business in 1997. In 2002, he was promoted,to ...
... (NEDA) Educators Seminar Thursday, October,4 in San Diego Informs Teachers, Administrators on ... ... NEW YORK, Sept. 27 Educators are in a unique,position to save ... eating disorders. For this reason, the National Eating Disorders Association will ...
... Reps. Berry, Moran, McMorris Rodgers, and Weiner, ... Association (NCPA) today applauds the official launch,of the ... is to preserve patient access to community,pharmacies by ... system,that devalues these small business owners who often ...
Cached Medicine News:Health News:SigmaSoft International Partners with Netrics to Create MedDRA and WHODrug Productivity Tool 2Health News:Donation of $15,000 and Hard Work Allows a Family in Need to Move into New Home 2Health News:Climate may increase heat-related deaths by 2050s, says Mailman School of PH study 2Health News:Wyeth Announces Election of Bernard Poussot as CEO of Company Effective January 1, 2008 2Health News:Spectrum of Eating Disorders - from Anorexia to Obesity - are Cause for Rising Concern among K-12 Students and Educators 2Health News:Congressional Community Pharmacy Coalition To Protect Community Pharmacies and Preserve Patient Access 2Health News:Congressional Community Pharmacy Coalition To Protect Community Pharmacies and Preserve Patient Access 3
Ovarian Cancer Test...
Test for prostatic acid phosphatase...
... If you could imagine the ultimate ... it maximize efficiency? Would its control systems ... flexible enough to quickly adapt to different ... you no longer need to imagine this ...
... world's first Windows 2000 notebook PC ... allows data sharing with other Windows ... Microsoft Office 2000. Data and waveforms ... large, sharp 14.1-inch TFT screen with ...
Medicine Products: